NCT Number: NCT03206034
Stylistic Memory Enhancement
Impairments in higher level cognitive processing, such as new learning and memory, are common in Multiple Sclerosis (MS) and negatively impact multiple aspects of everyday life, including occupational and social functioning. Despite this, few studies have attempted to remediate these cognitive deficits in order to improve everyday functioning. While not applied in traditional rehabilitation protocols as of yet, many techniques from cognitive psychology significantly improve learning and memory in healthy persons. These techniques include the generation effect (GE), the spacing effect (SE), and the testing effect (TE). These techniques have recently been incorporated into an 8-session treatment protocol, Stylistic Memory Enhancement (SME), designed to teach participants about each of the techniques, train them on how to apply the techniques in daily life and practice their application to daily life memory demanding situations. The protocol includes teaching participants how to restructure a memory demanding situation in order to make optimal use of self-generation, spaced learning and self-testing. The objective of the study is to test the efficacy of the SME in an MS population.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–59 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Clinically definite MS between the ages of 18 and 59. Participants must have impairment in new learning (determined by an in-person screen) with intact language comprehension.
Exclusion criteria
- History of alcohol or drug abuse/dependence,
- Major psychiatric disturbance (e.g. bipolar disorder, schizophrenia) and neurological history other than MS.
- Corticosteroid use within the last month prior to the participation.
- Less than 1 month post most recent exacerbation.
Treatment and study plan
Primary outcomes
-
California Verbal Learning Test (CVLT-II- Total learning
Time frame: Baseline and post-intervention (5 weeks between testing sessions)
Measure of change in new learning
Secondary outcomes
-
Memory Functioning Questionnaire
Time frame: Baseline and post-intervention ( 5 weeks between testing sessions)
Measure of change in Self-report of everyday memory functioning
Sponsors and collaborators
Lead sponsor
Kessler Foundation
Other
Registry information
Acronym: SME
Important dates
- Study start
- 2013
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Jul 2, 2017
- Registry last updated
- Jul 2, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
NCT03963375
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
St Louis, Missouri, United States
View Trial DetailsIn Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging
NCT02511028
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bethesda, Maryland, United States
View Trial DetailsAccuracy of Motor Performance Perception in Multiple Sclerosis
NCT07175792
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Diepenbeek, Belgium
View Trial DetailsEffects of CTAR and PNF Exercises on Swallowing in Multiple Sclerosis
NCT07726667
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Gaziantep, Gaz, Turkey (Türkiye)
View Trial Details